CytomX Therapeutics

CytomX Therapeutics, headquartered in South San Francisco, develops Probody® therapeutics—engineered antibodies that activate selectively at tumor sites—to deliver safer, more effective cancer treatments. Its pipeline includes five clinical‑stage programs across multiple oncology indications, with additional assets in development. The proprietary Probody platform distinguishes CytomX by reducing off‑target toxicity while preserving potency, and the company emphasizes collaboration, integrity, and diversity to drive innovation. CytomX is committed to equitable access to its therapies and to fostering an inclusive workplace that values diverse perspectives.